drugset
drugset / Trial / NCT01250366

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

NCT01250366 ↗

Phase 1 Completed 70 enrolled Bristol-Myers Squibb
RandomizedFactorialTriple-blindTreatment

Summary

The purpose of this study is to determine the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects.

Timeline

Start
2010-10
Primary completion
2011-03
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986094 Small molecule 9 mg Oral
Subject BMS-986094 Small molecule 25 mg Oral
Subject BMS-986094 Small molecule 50 mg Oral
Subject BMS-986094 Small molecule 100 mg Oral
Background Ribavirin Small molecule 1000 mg Oral
Background Ribavirin Small molecule 1200 mg Oral

Indications

No indication recorded.